Suppr超能文献

血清 C-反应蛋白在 4 年内的个体内变化:对流行病学研究的启示。

Intra-individual variation in serum C-reactive protein over 4 years: an implication for epidemiologic studies.

机构信息

Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe St., Rm E6132, Baltimore, MD 21205, USA.

出版信息

Cancer Causes Control. 2010 Jun;21(6):847-51. doi: 10.1007/s10552-010-9511-z. Epub 2010 Feb 5.

Abstract

BACKGROUND

Data on long-term intra-individual variability in high-sensitivity C-reactive protein (hsCRP) are needed to determine whether one measurement adequately reflects usual levels in prospective studies of on the etiology of cancer and other chronic diseases; when not reflective, the ability to statistically detect modest to moderate associations is reduced. The authors estimated the size of this source of variability and consequent attenuation of the relative risk (RR).

METHODS

High-sensitivity C-reactive protein (hsCRP) concentration was measured using a high-sensitivity immunoturbidometric assay in sera collected at years 2, 4, and 6 from 50 men in the placebo arm of the Prostate Cancer Prevention Trial (PCPT). After natural logarithm-transformation of hsCRP, analysis of variance was used to estimate the within- and between-individual variances from which the intra-class correlation coefficient (ICC) was calculated.

RESULTS

The observed RR due to an ICC < 1 was calculated by e((ln true RR*ICC)) for a range of true RRs. The 4-year ICC was 0.66. Measuring hsCRP once and assuming no other error, if the true RRs were 1.50, 2.00, and 3.00 when comparing high with low concentration, then the observed RRs would be 1.31, 1.58, and 2.06, respectively.

CONCLUSION

Investigators planning to measure hsCRP only once should design adequately sized studies to preserve inferences for hypothesized modest to moderate RRs.

摘要

背景

需要了解高敏 C 反应蛋白(hsCRP)在个体内长期的变异性数据,以确定在癌症和其他慢性疾病病因的前瞻性研究中,一次测量是否充分反映了通常水平;如果不能反映,那么统计检测到适度到中度关联的能力就会降低。作者估计了这种变异性的大小及其对相对风险(RR)的衰减程度。

方法

在前列腺癌预防试验(PCPT)的安慰剂组中,从 50 名男性的血清中分别在第 2、4 和 6 年采集 hsCRP 浓度,使用高敏免疫比浊法进行测量。对 hsCRP 进行自然对数转换后,使用方差分析估计个体内和个体间的方差,从而计算出组内相关系数(ICC)。

结果

通过 e((ln true RR*ICC)) 计算了由于 ICC < 1 而导致的观察到的 RR,其中 true RR 的范围为 1.50、2.00 和 3.00。4 年 ICC 为 0.66。如果真实 RR 为 1.50、2.00 和 3.00 时,高浓度与低浓度相比,hsCRP 仅测量一次且假设没有其他误差,则观察到的 RR 分别为 1.31、1.58 和 2.06。

结论

计划仅测量 hsCRP 一次的研究人员应设计足够大的研究,以保留对假设适度到中度 RR 的推断。

相似文献

1
Intra-individual variation in serum C-reactive protein over 4 years: an implication for epidemiologic studies.
Cancer Causes Control. 2010 Jun;21(6):847-51. doi: 10.1007/s10552-010-9511-z. Epub 2010 Feb 5.
3
Intra-individual variability of high-sensitivity C-reactive protein in Chinese general population.
Int J Cardiol. 2012 May 17;157(1):75-9. doi: 10.1016/j.ijcard.2010.12.019. Epub 2011 Jan 6.
6
Within-subject variation of C-reactive protein and high-sensitivity C-reactive protein: A systematic review and meta-analysis.
PLoS One. 2024 Nov 1;19(11):e0304961. doi: 10.1371/journal.pone.0304961. eCollection 2024.
9
Prognostic usefulness of serial C-reactive protein measurements in ST-elevation acute myocardial infarction.
Am J Cardiol. 2013 Jan 1;111(1):26-30. doi: 10.1016/j.amjcard.2012.08.041. Epub 2012 Oct 2.
10
C-reactive protein and risk of colorectal adenoma according to celecoxib treatment.
Cancer Prev Res (Phila). 2011 Aug;4(8):1172-80. doi: 10.1158/1940-6207.CAPR-10-0403.

引用本文的文献

1
A randomized controlled pilot trial of anakinra for hemodialysis inflammation.
Kidney Int. 2022 Nov;102(5):1178-1187. doi: 10.1016/j.kint.2022.06.022. Epub 2022 Jul 19.
2
C-reactive Protein and Risk of OSA in Four US Cohorts.
Chest. 2021 Jun;159(6):2439-2448. doi: 10.1016/j.chest.2021.01.060. Epub 2021 Jan 30.
4
Association Between Inflammatory Diets, Circulating Markers of Inflammation, and Risk of Diverticulitis.
Clin Gastroenterol Hepatol. 2020 Sep;18(10):2279-2286.e3. doi: 10.1016/j.cgh.2019.11.011. Epub 2019 Nov 8.
5
Evaluation of Plasma Adenosine as a Marker of Cardiovascular Risk: Analytical and Biological Considerations.
J Am Heart Assoc. 2019 Aug 6;8(15):e012228. doi: 10.1161/JAHA.119.012228. Epub 2019 Aug 5.
6
Reproducibility of non-fasting plasma metabolomics measurements across processing delays.
Metabolomics. 2018 Sep 25;14(10):129. doi: 10.1007/s11306-018-1429-6.
7
Multiplex assay reliability and long-term intra-individual variation of serologic inflammatory biomarkers.
Cytokine. 2017 Feb;90:185-192. doi: 10.1016/j.cyto.2016.09.018. Epub 2016 Dec 9.
8
Inflammatory biomarker score and cancer: A population-based prospective cohort study.
BMC Cancer. 2016 Feb 10;16:80. doi: 10.1186/s12885-016-2115-6.
9
Circulating Inflammatory Mediators as Potential Prognostic Markers of Human Colorectal Cancer.
PLoS One. 2016 Feb 9;11(2):e0148186. doi: 10.1371/journal.pone.0148186. eCollection 2016.
10
A critical review of perfluorooctanoate and perfluorooctanesulfonate exposure and immunological health conditions in humans.
Crit Rev Toxicol. 2016;46(4):279-331. doi: 10.3109/10408444.2015.1122573. Epub 2016 Jan 13.

本文引用的文献

1
Tracking of high-sensitivity C-reactive protein after an initially elevated concentration: the JUPITER Study.
Clin Chem. 2009 Feb;55(2):305-12. doi: 10.1373/clinchem.2008.120642. Epub 2008 Dec 18.
3
C-reactive protein and colorectal cancer risk: a systematic review of prospective studies.
Int J Cancer. 2008 Sep 1;123(5):1133-40. doi: 10.1002/ijc.23606.
4
Intra-individual variation of plasma adipokine levels and utility of single measurement of these biomarkers in population-based studies.
Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2464-70. doi: 10.1158/1055-9965.EPI-07-0374.
7
C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients.
J Am Coll Cardiol. 2006 Apr 18;47(8 Suppl):C19-31. doi: 10.1016/j.jacc.2005.10.066.
10
The influence of finasteride on the development of prostate cancer.
N Engl J Med. 2003 Jul 17;349(3):215-24. doi: 10.1056/NEJMoa030660. Epub 2003 Jun 24.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验